Coated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors - PubMed
3 hours ago
- #CAR-T therapy
- #Oncolytic virus
- #Solid tumor treatment
- Researchers developed a 'double strike' strategy using coated oncolytic viruses (Epv@CMP) to enhance CD19 CAR-T therapy in gastrointestinal tumors.
- Epv@CMP combines B cell membrane-derived CD19 as an artificial antigen on tumor cells and an in situ produced bispecific T cell engager (BiTE) to boost CAR-T cell binding and cytotoxicity.
- The system also remodels the immunosuppressive tumor immune microenvironment (TIME) through oncolytic adenovirus activity, promoting tumor-specific viral replication and immune activation.
- In mouse models of colorectal and gastric cancer, Epv@CMP alone induced tumor regression, and its combination with CD19 CAR-T cells led to potent tumor elimination.
- The approach integrates oncolytic virotherapy with CAR-T immunotherapy, overcoming limitations of stable antigen targets in solid tumors.